Page Banner
Mayo Clinic Laboratories > Neurology > Peripheral neuropathy

Peripheral neuropathy

Webinar Peripheral Neuropathy New Paradigm Shift
Patient Spotlight An uncommon antibody, a life restored: Jori Pearson

Expert-backed testing to establish diagnosis 

Lab testing is a powerful tool to assist physicians in identifying the causes of a patient’s peripheral neuropathy symptoms. Mayo Clinic Laboratories offers testing to identify peripheral autoimmune neuropathy with axonal or demyelinating causes, as well as next-generation sequencing (NGS) to help establish whether a peripheral neuropathy is genetic in nature.

Autoimmune peripheral neuropathy Autoimmune peripheral neuropathy
Autoimmune peripheral neuropathy

Our biomarker evaluations differentiate between peripheral autoimmune neuropathies that have either axonal or demyelinating causes. Treatment response differs depending on the underlying cause, and our expert-backed evaluations provide accurate results that set patients on the best treatment path.

Hereditary peripheral neuropathy Hereditary peripheral neuropathy
Hereditary peripheral neuropathy

Our hereditary peripheral neuropathy test menu includes both comprehensive and targeted NGS panels to assist in identifying genetic causes across the spectrum of peripheral neuropathies. A specific genetic diagnosis directly informs prognosis and impacts appropriate treatment and management, including use of gene-specific therapies.

News and updates

The latest

Neurofascin 155 IgG4 antibodies, a specific marker of chronic inflammatory demyelinating polyradiculoneuropathy featured image
Neurofascin 155 IgG4 antibodies, a specific marker of chronic inflammatory demyelinating polyradiculoneuropathy

Find out how our testing uses neurofascin 155 IgG4 antibodies as a specific marker of chronic inflammatory demyelinating polyradiculoneuropathy.

Learn more

No posts available.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.

(BETA) Choose a language to view this content in:
About the translation.